iShares iBoxx $ High Yield Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65, while State Street SPDR S&P Biotech ETF trades at $154.21. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| HYG | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $81.32 | $164.28 |
52-Week Low | $78.72 | $85.16 |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →